- Home
- DFLI vs LPCN Comparison
DFLI vs LPCN Comparison
Compare DFLI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFLI | LPCN |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 18.7M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | DFLI | LPCN |
|---|---|---|
| Price | $0.91 | $2.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 249.6K | 30.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,630,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.30 | $1.81 |
| 52 Week High | $5.15 | $12.37 |
Technical Indicators
Market Signals| Indicator | DFLI | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.45 |
| Support Level | N/A | $2.00 |
| Resistance Level | N/A | $2.27 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 12.50 |
Price Performance
Historical ComparisonAbout DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.